Rankings
▼
Calendar
ADMA FY 2021 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena
ADMA
ADMA Biologics, Inc.
$4B
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$81M
+91.7% YoY
Gross Profit
$1M
1.4% margin
Operating Income
-$58M
-72.1% margin
Net Income
-$72M
-88.5% margin
EPS (Diluted)
$-0.61
Cash Flow
Operating Cash Flow
-$112M
Free Cash Flow
-$126M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$276M
Total Liabilities
$135M
Stockholders' Equity
$141M
Cash & Equivalents
$51M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$81M
$42M
+91.7%
Gross Profit
$1M
-$19M
+106.2%
Operating Income
-$58M
-$65M
+10.1%
Net Income
-$72M
-$76M
+5.4%
← Q4 2020
All Quarters
Q1 2021 →